News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
147,231 Results
Type
Article (8014)
Company Profile (34)
Press Release (139183)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (43905)
Career Advice (243)
Deals (5271)
Drug Delivery (16)
Drug Development (21620)
Employer Resources (35)
FDA (2616)
Job Trends (3632)
News (72910)
Policy (5281)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (2)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (2)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (2)
2024 Genetown Standard (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 Pharm Country Standard (1)
Academia (921)
Accelerated approval (1)
Adcomms (3)
Allergies (23)
Alliances (12143)
ALS (30)
Alzheimer's disease (552)
Antibody-drug conjugate (ADC) (27)
Approvals (2622)
Artificial intelligence (76)
Autoimmune disease (5)
Automation (5)
Bankruptcy (31)
Best Places to Work (3208)
BIOSECURE Act (1)
Biosimilars (19)
Biotechnology (24)
Bladder cancer (27)
Brain cancer (8)
Breast cancer (102)
Cancer (669)
Cardiovascular disease (72)
Career advice (226)
Career pathing (8)
CAR-T (41)
Cell therapy (110)
Cervical cancer (2)
Clinical research (16921)
Collaboration (240)
Compensation (33)
Complete response letters (3)
COVID-19 (705)
CRISPR (18)
C-suite (98)
Cystic fibrosis (37)
Data (793)
Denatured (1)
Depression (12)
Diabetes (65)
Diagnostics (1561)
Digital health (2)
Diversity, equity & inclusion (9)
Drug discovery (38)
Drug pricing (9)
Drug shortages (3)
Duchenne muscular dystrophy (35)
Earnings (11255)
Editorial (7)
Employer branding (7)
Employer resources (33)
Events (22919)
Executive appointments (244)
FDA (2893)
Featured Employer (13)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (247)
Gene editing (38)
Generative AI (8)
Gene therapy (84)
GLP-1 (174)
Government (933)
Guidances (13)
Healthcare (3907)
Huntington's disease (3)
IgA nephropathy (6)
Immunology and inflammation (23)
Indications (9)
Infectious disease (740)
Inflammatory bowel disease (49)
Influenza (11)
Intellectual property (25)
Interviews (36)
IPO (2071)
IRA (5)
Job creations (626)
Job search strategy (203)
Kidney cancer (2)
Labor market (7)
Layoffs (88)
Leadership (5)
Legal (887)
Liver cancer (14)
Lung cancer (84)
Lymphoma (39)
Machine learning (3)
Management (11)
Manufacturing (56)
MASH (23)
Medical device (1807)
Medtech (1809)
Mergers & acquisitions (3322)
Metabolic disorders (174)
Multiple sclerosis (20)
NASH (5)
Neurodegenerative disease (29)
Neuropsychiatric disorders (8)
Neuroscience (718)
NextGen: Class of 2025 (1279)
Non-profit (1413)
Northern California (638)
Now hiring (6)
Obesity (86)
Opinion (49)
Ovarian cancer (13)
Pain (18)
Pancreatic cancer (22)
Parkinson's disease (54)
Partnered (5)
Patents (50)
Patient recruitment (27)
Peanut (9)
People (18262)
Pharmaceutical (7)
Phase I (5061)
Phase II (7211)
Phase III (5849)
Pipeline (316)
Policy (24)
Postmarket research (670)
Preclinical (3263)
Press Release (33)
Prostate cancer (34)
Psychedelics (11)
Radiopharmaceuticals (49)
Rare diseases (109)
Real estate (1224)
Recruiting (15)
Regulatory (3951)
Reports (8)
Research institute (1027)
Resumes & cover letters (25)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (18)
Series A (61)
Series B (19)
Sickle cell disease (24)
Southern California (533)
Special edition (1)
Spinal muscular atrophy (66)
Sponsored (14)
Startups (1186)
State (1)
Stomach cancer (3)
Supply chain (9)
Tariffs (2)
The Weekly (3)
United States (5681)
Vaccines (138)
Venture capitalists (8)
Weight loss (37)
Women's health (7)
Worklife (2)
Date
Today (73)
Last 7 days (245)
Last 30 days (723)
Last 365 days (8468)
2025 (2597)
2024 (9001)
2023 (10277)
2022 (13054)
2021 (14308)
2020 (12615)
2019 (10140)
2018 (7760)
2017 (7933)
2016 (7642)
2015 (8249)
2014 (6021)
2013 (4813)
2012 (4938)
2011 (5216)
2010 (4412)
Location
Africa (163)
Alabama (12)
Alaska (4)
Arizona (32)
Arkansas (2)
Asia (7989)
Australia (1355)
California (1421)
Canada (619)
China (105)
Colorado (71)
Connecticut (71)
Delaware (34)
Europe (22092)
Florida (161)
Georgia (48)
Idaho (9)
Illinois (100)
India (2)
Indiana (54)
Iowa (2)
Japan (39)
Kansas (11)
Kentucky (4)
Louisiana (3)
Maine (38)
Maryland (173)
Massachusetts (1297)
Michigan (75)
Minnesota (61)
Missouri (21)
Montana (5)
Nebraska (6)
Nevada (14)
New Hampshire (14)
New Jersey (393)
New Mexico (21)
New York (515)
North Carolina (218)
North Dakota (2)
Northern California (638)
Ohio (67)
Oklahoma (6)
Oregon (19)
Pennsylvania (335)
Puerto Rico (2)
Rhode Island (13)
South America (201)
South Carolina (3)
Southern California (533)
Tennessee (19)
Texas (235)
Utah (68)
Virginia (32)
Washington D.C. (8)
Washington State (139)
Wisconsin (12)
147,231 Results for "calgary scientific".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
Arch Biopartners Inc. announced today that the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
June 18, 2024
·
5 min read
Business
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary’s Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
March 15, 2024
·
5 min read
Press Releases
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
April 16, 2025
·
4 min read
The Alberta Cancer Foundation, Alberta Health Services and the University of Calgary announce largest donation in Alberta Health Service’s history to the new Calgary Cancer Centre
The Alberta Cancer Foundation, Alberta Health Services and the University of Calgary are thrilled to announce a historic and transformational $50 million donation to the Calgary Cancer Centre from the Arthur J.E. Child Foundation.
June 28, 2023
·
7 min read
Press Releases
Syantra, Inc. Announces Chair of Scientific Advisory Board and New Members
February 11, 2025
·
4 min read
Press Releases
Eurobio Scientific: 2024 annual results
April 29, 2025
·
7 min read
Press Releases
Krystal Biotech to Present at Upcoming Scientific Conferences
April 25, 2025
·
2 min read
Press Releases
INOVIO to Present at Upcoming Scientific Conferences
April 9, 2025
·
1 min read
Press Releases
Interius BioTherapeutics to Present at Upcoming Scientific Meetings
April 17, 2025
·
2 min read
Press Releases
Scientific Industries Secures New Funding to Advance its SBI Bioprocessing Division
April 23, 2025
·
3 min read
1 of 14,724
Next
